Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to 50.21%.

  • Fortress Biotech's EBT Margin rose 2322100.0% to 50.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 120.06%, marking a year-over-year increase of 690800.0%. This contributed to the annual value of 209.0% for FY2024, which is 272200.0% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's EBT Margin is 50.21%, which was up 2322100.0% from 218.43% recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's EBT Margin ranged from a high of 50.21% in Q3 2025 and a low of 465.29% during Q1 2023
  • For the 5-year period, Fortress Biotech's EBT Margin averaged around 225.59%, with its median value being 238.04% (2021).
  • Examining YoY changes over the last 5 years, Fortress Biotech's EBT Margin showed a top increase of 2905800bps in 2023 and a maximum decrease of -2683100bps in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's EBT Margin stood at 338.46% in 2021, then fell by -3bps to 347.45% in 2022, then soared by 59bps to 143.41% in 2023, then fell by -20bps to 171.82% in 2024, then skyrocketed by 129bps to 50.21% in 2025.
  • Its EBT Margin stands at 50.21% for Q3 2025, versus 218.43% for Q2 2025 and 166.12% for Q1 2025.